Seeking possible gene therapy treatment for Huntingdon’s Disease and Canavan Disease, Penn is further developing its relationship with Passage Bio, which has optioned two new possible therapies from Penn. Jim Wilson, MD, PhD, director of the Penn Gene Therapy Program, and a co-founder of Passage Bio, said there’s a “joint quest to develop transformative therapies for patients with devastating CNS (central nervous system) disorders.”
